numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON® LDLp Test System

Core Insights - numares Health has expanded its operations into the ASEAN region, receiving regulatory approval in Malaysia for the AXINON® LDLp Test System and securing its first contract with BioD Medica [1][2] Group 1: Company Overview - numares Health is a pioneering metabolomics company that provides multidimensional biomarker insights and clinical pathways aimed at optimal patient care [4] - The company utilizes a highly automated digital conversion of biochemical pathways to measure hundreds of biomarkers from a single minimally-processed sample, ensuring precise and scalable workflows [4] Group 2: Product Details - The AXINON® LDLp Test System measures the concentration, size, and distribution of lipoprotein particles (LDL-p), offering a more accurate assessment of cardiovascular disease (CVD) risk compared to standard lipid profile tests [3][5] - The system enhances sensitivity and specificity, guiding treatment pathways and enabling earlier detection of complex conditions [5][6] Group 3: Market Context - Cardiovascular diseases are the leading cause of death globally, with lipids being critical biomarkers for assessing CVD risk [3] - The AXINON® LDLp Test System aims to transform patient outcomes by providing healthcare professionals with innovative diagnostic devices [2][8]